20.01.2026 – 4min

Polyagonist Therapies in Obesity: A systems-level case study enabled by continuous in vivo phenotyping

Introduction 

Obesity and type 2 diabetes are not single-pathway diseases. They emerge from a complex disruption of whole-body energy homeostasis involving the gut, brain, pancreas, liver, adipose tissue and peripheral metabolic circuits.

For decades, pharmacological strategies focused on individual targets such as GLP-1, leptin or DPP-4. While these agents improved glycemic control and appetite regulation, long-term weight loss remained modest due to adaptive and compensatory mechanisms within the metabolic network.

A conceptual turning point came with the discovery of ghrelin – the first circulating orexigenic hormone. This work, pioneered by Matthias Tschöp, revealed how strongly the gut communicates with the brain to regulate appetite, energy expenditure and adiposity.

Today, dual and triple receptor agonists targeting GLP-1, GIP and glucagon represent a major therapeutic breakthrough. Their development relied not only on molecular engineering but also on continuous, high-resolution metabolic phenotyping platforms capable of resolving dynamic whole-body adaptations in vivo.

From Ghrelin to the Gut-Brain Metabolic Network 

The discovery of ghrelin introduced a systems-level view of metabolic regulation. Experimental studies demonstrated that ghrelin increases appetite, suppresses fat oxidation, alters energy expenditure and reshapes hypothalamic feeding circuits.

Subsequent human studies revealed paradoxically reduced circulating ghrelin levels in obesity, reinforcing a critical insight: targeting single hormones is insufficient because metabolic regulation is governed by interconnected, adaptive networks rather than linear pathways.

This realization laid the scientific foundation for polyagonist drug design.

The Rationale Behind Dual and Triple Agonists

Polyagonist strategies emerged from the understanding that GLP-1, GIP and glucagon receptors operate within coordinated metabolic circuits. Simultaneous activation allows synergistic effects that exceed those achievable by single-receptor drugs.

GLP-1 – Satiety, Glucose Control and Central Appetite Regulation
GLP-1 enhances glucose-dependent insulin secretion, activates POMC neurons, inhibits NPY/AgRP signaling, slows gastric emptying and improves hepatic insulin sensitivity.

GIP – Insulin Potentiation and Lipid Handling
GIP potentiates insulin secretion, improves postprandial lipid handling in adipose tissue and modulates central feeding circuits. When combined with GLP-1, it enhances appetite suppression and metabolic flexibility.

Glucagon – Energy Expenditure and Thermogenesis
Glucagon receptor activation increases cAMP-PKA signaling, stimulating hepatic fat oxidation, adipose lipolysis and brown adipose tissue thermogenesis. In triagonist designs, glucagon’s hyperglycemic potential must be precisely balanced by GLP-1 and GIP actions.

Why Continuous Phenotyping is the Critical Enabler

Polyagonists do not act statically; they reshape metabolism across circadian cycles and feeding states. Discrete “snapshot” measurements (like manual food weighing or glucose strips) fail to capture the nuances of these drugs.

To truly understand a polyagonist’s efficacy, researchers require an automated, indirect calorimetry environment that provides minute-resolution assessment of:

• Energy Expenditure (EE): Detecting transient elevations immediately following dosing.
• Respiratory Exchange Ratio (RER): Mapping the switch between carbohydrate and fat oxidation.
• Feeding Microstructure: Analyzing not just how much is eaten, but meal frequency, duration, and size.
• Locomotor Activity: Differentiating between metabolic thermogenesis and physical movement.
• Circadian Rhythms: Ensuring the drug maintains or restores healthy metabolic timing.

The PhenoMaster Advantage: By integrating these parameters into a single, undisturbed home-cage environment, researchers can identify the “metabolic signature” of a drug—the exact moment and mechanism by which a polyagonist alters the subject’s physiology.

Metabolic Signatures of Success 

Continuous monitoring uncovered dynamic responses that would otherwise remain invisible:

• Transient EE elevations following dosing
• Sustained nocturnal fat oxidation
• Reorganization of meal size and frequency
• Improved alignment between feeding behavior and circadian energy utilization

These signatures explain why polyagonists achieve durable metabolic benefits beyond appetite suppression alone.

High-Resolution Metabolic Phenotyping for Next-Generation Obesity Therapies

• Track how drugs change whole-body energy use across the full circadian cycle
• See how treatments shift substrate uses toward lipid oxidation or glucose
• Detect changes in satiety, nocturnal feeding, and inter-meal intervals
• Important for drug safety, metabolic balance, and animal welfare
• Quantify treatment-induced weight loss or gain over time
• Link metabolic changes to activity and circadian rhythms

Trusted by leading metabolic and obesity research groups worldwide.Polyagonist strategies emerged from the understanding that GLP-1, GIP and glucagon receptors operate within coordinated metabolic circuits. Simultaneous activation allows synergistic effects that exceed those achievable by single-receptor drugs.

GLP-1 – Satiety, Glucose Control and Central Appetite Regulation
GLP-1 enhances glucose-dependent insulin secretion, activates POMC neurons, inhibits NPY/AgRP signaling, slows gastric emptying and improves hepatic insulin sensitivity.

GIP – Insulin Potentiation and Lipid Handling
GIP potentiates insulin secretion, improves postprandial lipid handling in adipose tissue and modulates central feeding circuits. When combined with GLP-1, it enhances appetite suppression and metabolic flexibility.

Glucagon – Energy Expenditure and Thermogenesis
Glucagon receptor activation increases cAMP-PKA signaling, stimulating hepatic fat oxidation, adipose lipolysis and brown adipose tissue thermogenesis. In triagonist designs, glucagon’s hyperglycemic potential must be precisely balanced by GLP-1 and GIP actions.

Let’s talk about your next study

Key Findings in Polyagonist Development

Continuous phenotyping uncovered dynamic adaptations such as EE spikes, nocturnal fat oxidation and feeding-structure changes. These insights cannot be captured with single time-point measurements. 

Circadian Changes of Locomotor Activity and Energy Expenditure in C57Bl6 Mice

GLP-1 effects
• Reduced meal size
• Prolonged satiety
• Suppression of nocturnal hyperphagia

GIP effects
• Amplified insulinotropic response
• Improved postprandial metabolic handling

Glucagon effects
• Increased energy expenditure
• Elevated fat oxidation
• Enhanced thermogenic activity

Combined polyagonist outcomes
Preclinical rodent studies consistently demonstrated:
• 25–30% body weight reduction
• Normalization of glucose tolerance
• Reversal of hepatic steatosis
• Sustained 24-hour metabolic improvements

Translational Impact and Recognition

Continuous phenotyping has enabled rational receptor-balance optimization, informing dose selection and improving translational predictability. Dual agonists such as tirzepatide now achieve weight-loss efficacy approaching bariatric surgery outcomes.

The importance of this field was recently underscored by the Rolf Luft Award 2026, awarded to Professor Richard DiMarchi and Professor Matthias Tschöp. Their work in peptide chemistry and polyagonist development has redefined the treatment landscape for diabetes and obesity, supported by the Rolf Luft Foundation and the Karolinska Institute.

Conclusion 

The evolution of polyagonist therapies illustrates a shift from single-target pharmacology toward systems-level intervention. High-resolution continuous phenotyping remains the gold standard for this transition, allowing us to see not just if a therapy works, but how it redefines the symphony of whole-body metabolism. 

More news

Micro-Environmental Humidity and Temperature in Rodent Metabolic Research

by Pierre-Louis Ruffault, PhD Cage-level humidity and temperature in rodent metabolic research play a critical yet often underestimated role in shaping thermogenesis, energy expenditure, and...

Learn more

From Preclinical Motion to Clinical Insight: Bridging the Translational Gap with 3D Kinematic Gait Analysis

Motor function is a critical parameter  in CNS drug development. Subtle changes in gait and posture often precede overt clinical symptoms in neurological and neurodegenerative...

Learn more

Autism Awareness Month: Advancing Preclinical Insights with Mouse Models

Autism Spectrum Disorder (ASD) is a multifaceted neurodevelopmental condition characterized by social communication deficits, restricted interests, and repetitive behaviors. While our clinical understanding of ASD...

Learn more

The Rhythm of Life: Prof. Paul Petrus on How Our Body’s Clock Shapes Metabolism and Health

Join us for an exclusive interview with Prof. Paul Petrus from the Petrus Lab. His research focuses on endocrinology and diabetes, with a particular interest...

Learn more

The Expanding Impact of PhenoMaster: Fueling Scientific Discovery

PhenoMaster. A story of Scientific Trust.

Learn more

A Visionary in Neuroscience: Dr. Diego Bohórquez on Healing the Brain Through the Gut

A Visionary in Neuroscience: Dr. Diego Bohórquez on Healing the Brain Through the Gut

Learn more